ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1727

Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab

Zachary Wallace1, Li Yijia2, Manish Choudhary2, Julie Boucau3, Anusha Nathan3, May Yee Liew3, Gregory Edelstein2, Owen Glover3, Yumeko Kawano2, Rockib Uddin3, Rinki Deo2, Caitlin Marino3, Matthew Getz3, Zahra Reynolds4, karry Su4, Eliza Passell4, Mamadou Barry4, Rebecca Gilbert4, Dessie Tien4, Shruti Sagar4, Tammy Vyas4, Sarah Hammond2, Jatin Vyas4, Gaurav Gaiha4, Jacob Lemieux4, Mark Siedner4, Jonathan Li2, Amy Barczak4 and Jeffrey Sparks5, 1Massachusetts General Hospital, Newton, MA, 2Brigham and Women's Hospital, Boston, MA, 3Ragon Institute of MGH, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

Meeting: ACR Convergence 2024

Keywords: COVID-19, Disease-Modifying Antirheumatic Drugs (Dmards)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: Immunological Complications of Medical Therapy

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Individuals with rheumatic disease receiving certain immunosuppressive agents are at risk for severe COVID-19. However, it is unclear if rheumatic disease treatments affect the duration of SARS-CoV-2 viral shedding. Tumor necrosis factor inhibitors (TNFi) and rituximab (RTX) are common rheumatic disease treatments. RTX, in particular, is associated with a higher risk of severe COVID-19 and a possible risk factor for prolonged viral shedding. We sought to evaluate the association of TNFi and RTX use with duration of viral shedding.   

Methods: The POSITIVES study is an ongoing prospective cohort recruiting outpatients with a positive SARS-CoV-2 test, including those using a TNFi at infection or rituximab (RTX) in the previous 12 months. Participants self-collect anterior nasal swabs for viral PCR every 2-3 days for up to 6 samples over 2 weeks or until two consecutive negative SARS-CoV-2 PCR tests. We selected all outpatients receiving TNFi and RTX in the cohort and for each group, conducted 2:1 nearest neighbor propensity score matching on age, sex, race, ethnicity, number of prior COVID-19 vaccinations, and use of antivirals. We used survival methods to compare time to first negative viral PCR between those using immunosuppressants and the matched comparators.

Results: We have enrolled 24 TNFi users and 9 RTX users, matching them to 48 and 18 non-immunosuppressed participants, respectively. Participants were infected between February 2022 and April 2024. Age, sex, number of vaccines, and nirmatrelvir/ritonavir use were similar among TNFi/RTX users and matched comparators (Table 1). Most participants included in this analysis were vaccinated; the mean COVID-19 vaccination number in the TNFi and RTX groups, respectively, was 4.5 (1.0) and 4.1 (1.0), respectively. The median (IQR) time to the first negative PCR was not significantly different when comparing TNFi users vs comparators: 10 (7, 13) vs 7 (5, 11) days, respectively (Figure 1; Log-rank p=0.2). All RTX users had a dose of RTX in the 184 days prior to infection (median days from RTX infusion to infection: 91, range 18-184); the median number of RTX infusions in the 2 years prior to infection was 6 (range 2-13). The median (IQR) time to negative PCR in RTX users vs comparators was also similar: 7 (4.5, 11) vs 7 (5, 11) days, respectively (Figure 2; Log-rank p=0.8).

Conclusion: In this prospective study of outpatients with COVID-19 in the omicron era, TNFi and RTX users had similar durations of viral shedding vs non-immunosuppressed participants. High rates of vaccination, uptake of antivirals, and prior exposure to COVID-19 may improve COVID-19 outcomes in this population, especially RTX users. Assessing the duration of viral culture positivity and differences in viral load are important next steps in this cohort.  

Supporting image 1

Table 1: Baseline Characteristics of Participants

Supporting image 2

Figure 1: Time to negative PCR among TNFi users vs comparators

Supporting image 3

Figure 2: Time to negative PCR among RTX users vs comparators


Disclosures: Z. Wallace: Amgen, 2, 5, BioCryst, 2, MedPace, 2, PPD, 2, Sanofi, 5, Zenas, 2; L. Yijia: None; M. Choudhary: None; J. Boucau: None; A. Nathan: None; M. Liew: None; G. Edelstein: None; O. Glover: None; Y. Kawano: None; R. Uddin: None; R. Deo: None; C. Marino: None; M. Getz: None; Z. Reynolds: None; k. Su: None; E. Passell: None; M. Barry: None; R. Gilbert: None; D. Tien: None; S. Sagar: None; T. Vyas: None; S. Hammond: Cidara, 5, F2G, 5, GlaxoSmithKlein(GSK), 5, Melinta, 2, Pfizer, 2, Roche, 1, Scynexis, 5, Seres Therapeutics, 2; J. Vyas: None; G. Gaiha: None; J. Lemieux: None; M. Siedner: None; J. Li: None; A. Barczak: None; J. Sparks: Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Gilead, 2, Janssen, 2, Pfizer, 2, UCB, 2.

To cite this abstract in AMA style:

Wallace Z, Yijia L, Choudhary M, Boucau J, Nathan A, Liew M, Edelstein G, Glover O, Kawano Y, Uddin R, Deo R, Marino C, Getz M, Reynolds Z, Su k, Passell E, Barry M, Gilbert R, Tien D, Sagar S, Vyas T, Hammond S, Vyas J, Gaiha G, Lemieux J, Siedner M, Li J, Barczak A, Sparks J. Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/duration-of-sars-cov-2-viral-shedding-after-infection-among-patients-with-rheumatic-disease-using-tumor-necrosis-factor-inhibitors-or-rituximab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/duration-of-sars-cov-2-viral-shedding-after-infection-among-patients-with-rheumatic-disease-using-tumor-necrosis-factor-inhibitors-or-rituximab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology